25 XP   0   0   10

Bal Pharma Limited
Buy, Hold or Sell?

Let's analyse Bal Pharma Limited together

PenkeI guess you are interested in Bal Pharma Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Bal Pharma Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Bal Pharma Limited

I send you an email if I find something interesting about Bal Pharma Limited.

Quick analysis of Bal Pharma Limited (30 sec.)










What can you expect buying and holding a share of Bal Pharma Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR0.05
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR40.31
Expected worth in 1 year
INR53.49
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
INR17.13
Return On Investment
18.8%

For what price can you sell your share?

Current Price per Share
INR91.20
Expected price per share
INR81.15 - INR126.00
How sure are you?
50%

1. Valuation of Bal Pharma Limited (5 min.)




Live pricePrice per Share (EOD)

INR91.20

Intrinsic Value Per Share

INR-263.24 - INR-27.92

Total Value Per Share

INR-222.93 - INR12.39

2. Growth of Bal Pharma Limited (5 min.)




Is Bal Pharma Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$7.6m$7m$625.1k8.2%

How much money is Bal Pharma Limited making?

Current yearPrevious yearGrowGrow %
Making money$308.6k$673.3k-$364.7k-118.2%
Net Profit Margin0.8%2.0%--

How much money comes from the company's main activities?

3. Financial Health of Bal Pharma Limited (5 min.)




What can you expect buying and holding a share of Bal Pharma Limited? (5 min.)

Welcome investor! Bal Pharma Limited's management wants to use your money to grow the business. In return you get a share of Bal Pharma Limited.

What can you expect buying and holding a share of Bal Pharma Limited?

First you should know what it really means to hold a share of Bal Pharma Limited. And how you can make/lose money.

Speculation

The Price per Share of Bal Pharma Limited is INR91.20. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Bal Pharma Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Bal Pharma Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR40.31. Based on the TTM, the Book Value Change Per Share is INR3.30 per quarter. Based on the YOY, the Book Value Change Per Share is INR3.25 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR0.99 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Bal Pharma Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.020.0%0.020.0%0.040.0%0.010.0%0.010.0%
Usd Book Value Change Per Share0.040.0%0.040.0%0.040.0%0.010.0%0.010.0%
Usd Dividend Per Share0.010.0%0.010.0%0.010.0%0.010.0%0.010.0%
Usd Total Gains Per Share0.050.1%0.050.1%0.050.1%0.010.0%0.020.0%
Usd Price Per Share0.80-0.80-1.29-0.79-0.83-
Price to Earnings Ratio41.20-41.20-30.39-22.91-38.93-
Price-to-Total Gains Ratio15.66-15.66-25.76-24.40-37.96-
Price to Book Ratio1.66-1.66-2.92-1.82-1.93-
Price-to-Total Gains Ratio15.66-15.66-25.76-24.40-37.96-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.0944
Number of shares913
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share0.040.01
Usd Total Gains Per Share0.050.01
Gains per Quarter (913 shares)46.9113.48
Gains per Year (913 shares)187.6453.91
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
143144178341944
286289366693998
313043355410358152
417357874213878206
521672293017297260
62598671118207116314
730210111306241136368
834511561494276155422
938913001682310175476
1043214451870345194530

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%9.01.00.090.0%14.02.00.087.5%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%8.02.00.080.0%13.03.00.081.3%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%13.00.03.081.3%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%9.01.00.090.0%14.02.00.087.5%

Fundamentals of Bal Pharma Limited

About Bal Pharma Limited

Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India, Uzbekistan, Guatemala, and Malta. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, etc.; and various formulations. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company also exports its products. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.

Fundamental data was last updated by Penke on 2024-03-23 07:11:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Bal Pharma Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Bal Pharma Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Bal Pharma Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 0.8% means that ₹0.01 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Bal Pharma Limited:

  • The MRQ is 0.8%. The company is not making a profit/loss.
  • The TTM is 0.8%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ0.8%TTM0.8%0.0%
TTM0.8%YOY2.0%-1.2%
TTM0.8%5Y-0.1%+1.0%
5Y-0.1%10Y0.7%-0.8%
1.1.2. Return on Assets

Shows how efficient Bal Pharma Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Bal Pharma Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.8% Return on Assets means that Bal Pharma Limited generated ₹0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Bal Pharma Limited:

  • The MRQ is 0.8%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.8%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.8%TTM0.8%0.0%
TTM0.8%YOY2.2%-1.3%
TTM0.8%5Y0.3%+0.6%
5Y0.3%10Y0.9%-0.7%
1.1.3. Return on Equity

Shows how efficient Bal Pharma Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Bal Pharma Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 4.0% Return on Equity means Bal Pharma Limited generated ₹0.04 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Bal Pharma Limited:

  • The MRQ is 4.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 4.0%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ4.0%TTM4.0%0.0%
TTM4.0%YOY9.6%-5.5%
TTM4.0%5Y1.0%+3.1%
5Y1.0%10Y3.2%-2.2%

1.2. Operating Efficiency of Bal Pharma Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Bal Pharma Limited is operating .

  • Measures how much profit Bal Pharma Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Bal Pharma Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 5.6% means the company generated ₹0.06  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Bal Pharma Limited:

  • The MRQ is 5.6%. The company is operating less efficient.
  • The TTM is 5.6%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ5.6%TTM5.6%0.0%
TTM5.6%YOY5.5%+0.1%
TTM5.6%5Y4.0%+1.6%
5Y4.0%10Y4.5%-0.5%
1.2.2. Operating Ratio

Measures how efficient Bal Pharma Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.95 means that the operating costs are ₹0.95 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Bal Pharma Limited:

  • The MRQ is 0.947. The company is less efficient in keeping operating costs low.
  • The TTM is 0.947. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.947TTM0.9470.000
TTM0.947YOY0.9480.000
TTM0.9475Y0.958-0.011
5Y0.95810Y0.954+0.004

1.3. Liquidity of Bal Pharma Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Bal Pharma Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.09 means the company has ₹1.09 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Bal Pharma Limited:

  • The MRQ is 1.090. The company is just able to pay all its short-term debts.
  • The TTM is 1.090. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.090TTM1.0900.000
TTM1.090YOY1.114-0.024
TTM1.0905Y1.081+0.009
5Y1.08110Y1.147-0.066
1.3.2. Quick Ratio

Measures if Bal Pharma Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Bal Pharma Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.53 means the company can pay off ₹0.53 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Bal Pharma Limited:

  • The MRQ is 0.534. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.534. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.534TTM0.5340.000
TTM0.534YOY0.692-0.159
TTM0.5345Y0.629-0.096
5Y0.62910Y0.594+0.036

1.4. Solvency of Bal Pharma Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Bal Pharma Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Bal Pharma Limited to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.80 means that Bal Pharma Limited assets are financed with 79.7% credit (debt) and the remaining percentage (100% - 79.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Bal Pharma Limited:

  • The MRQ is 0.797. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.797. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.797TTM0.7970.000
TTM0.797YOY0.775+0.021
TTM0.7975Y0.786+0.011
5Y0.78610Y0.751+0.035
1.4.2. Debt to Equity Ratio

Measures if Bal Pharma Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Bal Pharma Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 391.1% means that company has ₹3.91 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Bal Pharma Limited:

  • The MRQ is 3.911. The company is unable to pay all its debts with equity. -1
  • The TTM is 3.911. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ3.911TTM3.9110.000
TTM3.911YOY3.446+0.465
TTM3.9115Y3.508+0.403
5Y3.50810Y3.010+0.498

2. Market Valuation of Bal Pharma Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Bal Pharma Limited generates.

  • Above 15 is considered overpriced but always compare Bal Pharma Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 41.20 means the investor is paying ₹41.20 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Bal Pharma Limited:

  • The EOD is 56.045. Based on the earnings, the company is expensive. -2
  • The MRQ is 41.204. Based on the earnings, the company is overpriced. -1
  • The TTM is 41.204. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD56.045MRQ41.204+14.841
MRQ41.204TTM41.2040.000
TTM41.204YOY30.389+10.815
TTM41.2045Y22.910+18.294
5Y22.91010Y38.931-16.022
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Bal Pharma Limited:

  • The EOD is -8.741. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.427. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.427. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.741MRQ-6.427-2.315
MRQ-6.427TTM-6.4270.000
TTM-6.427YOY8.864-15.290
TTM-6.4275Y-24.461+18.035
5Y-24.46110Y-18.974-5.487
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Bal Pharma Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.66 means the investor is paying ₹1.66 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Bal Pharma Limited:

  • The EOD is 2.263. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.663. Based on the equity, the company is underpriced. +1
  • The TTM is 1.663. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.263MRQ1.663+0.599
MRQ1.663TTM1.6630.000
TTM1.663YOY2.915-1.252
TTM1.6635Y1.823-0.160
5Y1.82310Y1.927-0.103
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Bal Pharma Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--3.2963.2960%3.251+1%0.443+644%1.208+173%
Book Value Per Share--40.30740.3070%37.010+9%35.573+13%35.514+13%
Current Ratio--1.0901.0900%1.114-2%1.081+1%1.147-5%
Debt To Asset Ratio--0.7970.7970%0.775+3%0.786+1%0.751+6%
Debt To Equity Ratio--3.9113.9110%3.446+13%3.508+11%3.010+30%
Dividend Per Share--0.9850.9850%0.938+5%0.787+25%0.857+15%
Eps--1.6271.6270%3.551-54%0.569+186%1.211+34%
Free Cash Flow Per Share---10.433-10.4330%12.173-186%4.849-315%0.805-1396%
Free Cash Flow To Equity Per Share--5.0065.0060%0.699+616%1.012+395%0.395+1166%
Gross Profit Margin---1.102-1.1020%-1.640+49%-1.031-6%-1.880+71%
Intrinsic Value_10Y_max---27.919--------
Intrinsic Value_10Y_min---263.239--------
Intrinsic Value_1Y_max--3.208--------
Intrinsic Value_1Y_min---6.110--------
Intrinsic Value_3Y_max--5.061--------
Intrinsic Value_3Y_min---36.023--------
Intrinsic Value_5Y_max--1.397--------
Intrinsic Value_5Y_min---85.064--------
Market Cap1441361280.000+26%1059685020.0001059685020.0000%1705294760.000-38%1044670840.000+1%1097220470.000-3%
Net Profit Margin--0.0080.0080%0.020-58%-0.001+117%0.007+22%
Operating Margin--0.0560.0560%0.055+1%0.040+39%0.045+23%
Operating Ratio--0.9470.9470%0.9480%0.958-1%0.954-1%
Pb Ratio2.263+26%1.6631.6630%2.915-43%1.823-9%1.927-14%
Pe Ratio56.045+26%41.20441.2040%30.389+36%22.910+80%38.931+6%
Price Per Share91.200+26%67.05067.0500%107.900-38%66.100+1%69.425-3%
Price To Free Cash Flow Ratio-8.741-36%-6.427-6.4270%8.864-173%-24.461+281%-18.974+195%
Price To Total Gains Ratio21.300+26%15.66015.6600%25.756-39%24.399-36%37.963-59%
Quick Ratio--0.5340.5340%0.692-23%0.629-15%0.594-10%
Return On Assets--0.0080.0080%0.022-62%0.003+222%0.009-13%
Return On Equity--0.0400.0400%0.096-58%0.010+317%0.032+28%
Total Gains Per Share--4.2824.2820%4.189+2%1.230+248%2.064+107%
Usd Book Value--7644264.0007644264.0000%7019088.000+9%6746570.400+13%6735345.187+13%
Usd Book Value Change Per Share--0.0400.0400%0.039+1%0.005+644%0.014+173%
Usd Book Value Per Share--0.4840.4840%0.444+9%0.427+13%0.426+13%
Usd Dividend Per Share--0.0120.0120%0.011+5%0.009+25%0.010+15%
Usd Eps--0.0200.0200%0.043-54%0.007+186%0.015+34%
Usd Free Cash Flow---1978668.000-1978668.0000%2308692.000-186%919665.600-315%152679.702-1396%
Usd Free Cash Flow Per Share---0.125-0.1250%0.146-186%0.058-315%0.010-1396%
Usd Free Cash Flow To Equity Per Share--0.0600.0600%0.008+616%0.012+395%0.005+1166%
Usd Market Cap17296335.360+26%12716220.24012716220.2400%20463537.120-38%12536050.080+1%13166645.640-3%
Usd Price Per Share1.094+26%0.8050.8050%1.295-38%0.793+1%0.833-3%
Usd Profit--308604.000308604.0000%673380.000-54%107884.800+186%232427.729+33%
Usd Revenue--36505944.00036505944.0000%33745740.000+8%29569538.400+23%26815281.592+36%
Usd Total Gains Per Share--0.0510.0510%0.050+2%0.015+248%0.025+107%
 EOD+5 -3MRQTTM+0 -0YOY+18 -185Y+25 -1110Y+22 -14

3.2. Fundamental Score

Let's check the fundamental score of Bal Pharma Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1556.045
Price to Book Ratio (EOD)Between0-12.263
Net Profit Margin (MRQ)Greater than00.008
Operating Margin (MRQ)Greater than00.056
Quick Ratio (MRQ)Greater than10.534
Current Ratio (MRQ)Greater than11.090
Debt to Asset Ratio (MRQ)Less than10.797
Debt to Equity Ratio (MRQ)Less than13.911
Return on Equity (MRQ)Greater than0.150.040
Return on Assets (MRQ)Greater than0.050.008
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Bal Pharma Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.508
Ma 20Greater thanMa 50101.060
Ma 50Greater thanMa 100111.748
Ma 100Greater thanMa 200108.338
OpenGreater thanClose95.000
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets3,131,723
Total Liabilities2,494,701
Total Stockholder Equity637,891
 As reported
Total Liabilities 2,494,701
Total Stockholder Equity+ 637,891
Total Assets = 3,131,723

Assets

Total Assets3,131,723
Total Current Assets2,281,559
Long-term Assets850,161
Total Current Assets
Cash And Cash Equivalents 14,872
Short-term Investments 75,939
Net Receivables 950,813
Inventory 980,050
Other Current Assets 259,885
Total Current Assets  (as reported)2,281,559
Total Current Assets  (calculated)2,281,559
+/-0
Long-term Assets
Property Plant Equipment 621,792
Goodwill 38,286
Intangible Assets 104,570
Long-term Assets Other 104,745
Long-term Assets  (as reported)850,161
Long-term Assets  (calculated)869,393
+/- 19,232

Liabilities & Shareholders' Equity

Total Current Liabilities2,093,344
Long-term Liabilities401,357
Total Stockholder Equity637,891
Total Current Liabilities
Short-term Debt 1,004,761
Short Long Term Debt 1,004,761
Accounts payable 789,229
Other Current Liabilities 177,058
Total Current Liabilities  (as reported)2,093,344
Total Current Liabilities  (calculated)2,975,809
+/- 882,465
Long-term Liabilities
Long term Debt Total 305,231
Capital Lease Obligations 20,799
Other Liabilities 83,875
Long-term Liabilities  (as reported)401,357
Long-term Liabilities  (calculated)409,905
+/- 8,548
Total Stockholder Equity
Common Stock156,899
Retained Earnings 146,885
Accumulated Other Comprehensive Income 32,267
Other Stockholders Equity 301,840
Total Stockholder Equity (as reported)637,891
Total Stockholder Equity (calculated)637,891
+/-0
Other
Capital Stock156,899
Cash And Equivalents14,872
Cash and Short Term Investments 90,811
Common Stock Shares Outstanding 15,690
Current Deferred Revenue122,296
Liabilities and Stockholders Equity 3,131,723
Net Debt 1,295,120
Net Invested Capital 1,947,883
Net Tangible Assets 586,449
Net Working Capital 188,215
Property Plant and Equipment Gross 621,792
Short Long Term Debt Total 1,309,992



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-312009-03-312008-03-31
> Total Assets 
1,088,405
1,215,360
1,242,018
1,353,037
1,411,638
1,498,376
1,547,441
1,638,628
2,110,303
2,302,223
2,518,145
2,613,083
2,383,871
2,400,804
2,605,327
3,131,723
3,131,7232,605,3272,400,8042,383,8712,613,0832,518,1452,302,2232,110,3031,638,6281,547,4411,498,3761,411,6381,353,0371,242,0181,215,3601,088,405
   > Total Current Assets 
582,650
612,537
692,040
809,005
844,970
932,139
951,165
1,051,245
1,429,979
1,614,301
1,759,402
1,819,066
1,611,296
1,641,473
1,845,706
2,281,559
2,281,5591,845,7061,641,4731,611,2961,819,0661,759,4021,614,3011,429,9791,051,245951,165932,139844,970809,005692,040612,537582,650
       Cash And Cash Equivalents 
29,014
13,609
16,148
22,303
30,267
47,284
30,242
54,944
46,344
46,356
40,396
24,361
8,587
10,234
11,128
14,872
14,87211,12810,2348,58724,36140,39646,35646,34454,94430,24247,28430,26722,30316,14813,60929,014
       Short-term Investments 
0
0
0
0
0
0
0
0
0
24,609
13,310
17,097
26,479
29,475
49,717
75,939
75,93949,71729,47526,47917,09713,31024,609000000000
       Net Receivables 
0
0
0
0
0
0
457,137
454,002
569,812
663,619
701,404
954,396
899,816
994,775
1,036,476
950,813
950,8131,036,476994,775899,816954,396701,404663,619569,812454,002457,137000000
       Inventory 
254,500
238,861
286,224
322,144
336,595
336,870
317,142
358,152
417,542
547,307
664,934
697,511
677,113
603,853
743,956
980,050
980,050743,956603,853677,113697,511664,934547,307417,542358,152317,142336,870336,595322,144286,224238,861254,500
       Other Current Assets 
299,136
360,067
389,667
464,558
478,108
547,985
603,782
638,149
966,093
1,020,638
1,054,072
125,701
-699
3,136
4,429
259,885
259,8854,4293,136-699125,7011,054,0721,020,638966,093638,149603,782547,985478,108464,558389,667360,067299,136
   > Long-term Assets 
505,755
602,822
549,978
544,032
566,667
566,237
596,275
587,384
680,324
687,921
758,743
794,017
772,575
759,331
759,623
850,161
850,161759,623759,331772,575794,017758,743687,921680,324587,384596,275566,237566,667544,032549,978602,822505,755
       Property Plant Equipment 
459,282
553,273
497,508
484,443
476,655
476,160
505,590
480,920
555,282
571,422
634,131
644,778
637,695
575,087
572,751
621,792
621,792572,751575,087637,695644,778634,131571,422555,282480,920505,590476,160476,655484,443497,508553,273459,282
       Goodwill 
0
0
0
0
0
0
0
0
0
0
29,026
38,286
38,286
38,286
38,286
38,286
38,28638,28638,28638,28638,28629,0260000000000
       Long Term Investments 
0
0
0
0
0
0
172
3,083
3,344
2,990
5,291
24,980
0
0
0
0
000024,9805,2912,9903,3443,083172000000
       Intangible Assets 
0
0
0
0
0
0
1
486
46,288
46,693
44,738
57,119
64,282
72,482
83,016
104,570
104,57083,01672,48264,28257,11944,73846,69346,2884861000000
       Long-term Assets Other 
46,472
49,549
52,471
59,589
90,012
90,077
90,685
106,464
125,042
69,806
50,848
53,834
1
43,278
90,764
104,745
104,74590,76443,278153,83450,84869,806125,042106,46490,68590,07790,01259,58952,47149,54946,472
> Total Liabilities 
738,082
843,014
884,397
991,285
1,011,079
1,052,192
1,046,945
1,086,953
1,563,078
1,701,917
1,916,130
2,010,871
1,930,494
1,867,268
2,020,403
2,494,701
2,494,7012,020,4031,867,2681,930,4942,010,8711,916,1301,701,9171,563,0781,086,9531,046,9451,052,1921,011,079991,285884,397843,014738,082
   > Total Current Liabilities 
236,639
313,456
277,841
345,880
863,185
926,661
867,715
923,584
1,111,922
1,214,927
1,452,051
1,632,377
1,594,915
1,525,329
1,656,448
2,093,344
2,093,3441,656,4481,525,3291,594,9151,632,3771,452,0511,214,9271,111,922923,584867,715926,661863,185345,880277,841313,456236,639
       Short-term Debt 
0
0
1,621
8,851
445,294
443,597
427,499
401,379
500,915
562,872
749,366
947,452
961,520
863,988
773,882
1,004,761
1,004,761773,882863,988961,520947,452749,366562,872500,915401,379427,499443,597445,2948,8511,62100
       Short Long Term Debt 
0
0
0
0
0
0
530,554
27,031
37,117
562,872
749,366
947,452
953,089
808,189
766,263
1,004,761
1,004,761766,263808,189953,089947,452749,366562,87237,11727,031530,554000000
       Accounts payable 
13,737
17,434
4,725
5,877
269,217
320,564
335,309
385,349
468,511
513,613
452,616
473,379
386,740
471,665
655,639
789,229
789,229655,639471,665386,740473,379452,616513,613468,511385,349335,309320,564269,2175,8774,72517,43413,737
       Other Current Liabilities 
222,901
296,022
271,495
331,152
148,674
162,500
104,907
136,856
142,495
138,442
230,109
206,957
52,877
77,356
34,889
177,058
177,05834,88977,35652,877206,957230,109138,442142,495136,856104,907162,500148,674331,152271,495296,022222,901
   > Long-term Liabilities 
501,443
529,558
606,555
645,405
147,895
125,531
179,230
163,369
451,156
486,990
464,079
378,494
335,579
341,939
363,955
401,357
401,357363,955341,939335,579378,494464,079486,990451,156163,369179,230125,531147,895645,405606,555529,558501,443
       Long term Debt Total 
0
0
0
0
0
0
0
0
159,366
178,027
346,761
287,560
231,466
274,964
270,134
305,231
305,231270,134274,964231,466287,560346,761178,027159,36600000000
       Other Liabilities 
0
0
0
0
0
0
99,529
96,926
101,590
122,179
108,953
90,836
92,975
86,466
71,286
83,875
83,87571,28686,46692,97590,836108,953122,179101,59096,92699,529000000
       Deferred Long Term Liability 
0
0
0
0
0
0
48,656
48,246
45,921
45,921
43,900
56,145
63,380
71,891
77,825
91,415
91,41577,82571,89163,38056,14543,90045,92145,92148,24648,656000000
> Total Stockholder Equity
350,323
372,346
357,621
361,752
400,558
446,184
500,496
552,024
549,020
629,853
649,883
666,430
524,261
535,814
586,268
637,891
637,891586,268535,814524,261666,430649,883629,853549,020552,024500,496446,184400,558361,752357,621372,346350,323
   Common Stock
104,462
104,832
104,832
104,832
105,736
105,736
111,114
128,724
128,724
141,724
141,724
141,724
141,724
148,224
148,224
156,899
156,899148,224148,224141,724141,724141,724141,724128,724128,724111,114105,736105,736104,832104,832104,832104,462
   Retained Earnings 
69,932
90,662
76,373
80,452
0
0
189,302
201,063
198,059
218,442
244,337
265,129
125,863
94,519
135,813
146,885
146,885135,81394,519125,863265,129244,337218,442198,059201,063189,3020080,45276,37390,66269,932
   Capital Surplus 0000000000000000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
175,929
176,852
176,416
176,468
294,822
340,448
200,080
222,237
222,237
269,687
263,822
259,577
240,766
266,766
266,768
301,840
301,840266,768266,766240,766259,577263,822269,687222,237222,237200,080340,448294,822176,468176,416176,852175,929



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue3,042,162
Cost of Revenue-1,727,699
Gross Profit1,314,4631,314,463
 
Operating Income (+$)
Gross Profit1,314,463
Operating Expense-1,154,518
Operating Income169,350159,945
 
Operating Expense (+$)
Research Development0
Selling General Administrative34,236
Selling And Marketing Expenses54,058
Operating Expense1,154,51888,294
 
Net Interest Income (+$)
Interest Income121,865
Interest Expense-121,865
Other Finance Cost-121,865
Net Interest Income-121,865
 
Pretax Income (+$)
Operating Income169,350
Net Interest Income-121,865
Other Non-Operating Income Expenses0
Income Before Tax (EBT)47,485291,215
EBIT - interestExpense = 47,485
47,009
147,582
Interest Expense121,865
Earnings Before Interest and Taxes (EBIT)169,350169,350
Earnings Before Interest and Taxes (EBITDA)260,633
 
After tax Income (+$)
Income Before Tax47,485
Tax Provision-21,292
Net Income From Continuing Ops26,19326,193
Net Income25,717
Net Income Applicable To Common Shares25,718
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses2,882,217
Total Other Income/Expenses Net-121,865121,865
 

Technical Analysis of Bal Pharma Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Bal Pharma Limited. The general trend of Bal Pharma Limited is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Bal Pharma Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Bal Pharma Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 108.00 < 108.05 < 126.00.

The bearish price targets are: 88.95 > 81.20 > 81.15.

Tweet this
Bal Pharma Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Bal Pharma Limited. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Bal Pharma Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Bal Pharma Limited. The current macd is -5.15395341.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Bal Pharma Limited price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Bal Pharma Limited. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Bal Pharma Limited price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Bal Pharma Limited Daily Moving Average Convergence/Divergence (MACD) ChartBal Pharma Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Bal Pharma Limited. The current adx is 37.59.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Bal Pharma Limited shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Bal Pharma Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Bal Pharma Limited. The current sar is 102.00.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Bal Pharma Limited Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Bal Pharma Limited. The current rsi is 31.51. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Bal Pharma Limited Daily Relative Strength Index (RSI) ChartBal Pharma Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Bal Pharma Limited. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Bal Pharma Limited price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Bal Pharma Limited Daily Stochastic Oscillator ChartBal Pharma Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Bal Pharma Limited. The current cci is -94.61918378.

Bal Pharma Limited Daily Commodity Channel Index (CCI) ChartBal Pharma Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Bal Pharma Limited. The current cmo is -43.65043581.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Bal Pharma Limited Daily Chande Momentum Oscillator (CMO) ChartBal Pharma Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Bal Pharma Limited. The current willr is -88.8337469.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Bal Pharma Limited Daily Williams %R ChartBal Pharma Limited Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Bal Pharma Limited.

Bal Pharma Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Bal Pharma Limited. The current atr is 5.2517098.

Bal Pharma Limited Daily Average True Range (ATR) ChartBal Pharma Limited Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Bal Pharma Limited. The current obv is 7,429,401.

Bal Pharma Limited Daily On-Balance Volume (OBV) ChartBal Pharma Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Bal Pharma Limited. The current mfi is 42.97.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Bal Pharma Limited Daily Money Flow Index (MFI) ChartBal Pharma Limited Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Bal Pharma Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-24MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Bal Pharma Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Bal Pharma Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.508
Ma 20Greater thanMa 50101.060
Ma 50Greater thanMa 100111.748
Ma 100Greater thanMa 200108.338
OpenGreater thanClose95.000
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Bal Pharma Limited with someone you think should read this too:
  • Are you bullish or bearish on Bal Pharma Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Bal Pharma Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Bal Pharma Limited

I send you an email if I find something interesting about Bal Pharma Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Bal Pharma Limited.

Receive notifications about Bal Pharma Limited in your mailbox!